S&P 500   3,113.99 (+0.56%)
DOW   27,928.81 (+0.53%)
QQQ   202.57 (+0.56%)
CGC   15.33 (-3.22%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.28 (+0.82%)
ACB   2.85 (-13.37%)
F   8.95 (+1.82%)
PRI   131.16 (+0.74%)
BAC   32.88 (+0.55%)
DIS   144.93 (-1.51%)
S&P 500   3,113.99 (+0.56%)
DOW   27,928.81 (+0.53%)
QQQ   202.57 (+0.56%)
CGC   15.33 (-3.22%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.28 (+0.82%)
ACB   2.85 (-13.37%)
F   8.95 (+1.82%)
PRI   131.16 (+0.74%)
BAC   32.88 (+0.55%)
DIS   144.93 (-1.51%)
S&P 500   3,113.99 (+0.56%)
DOW   27,928.81 (+0.53%)
QQQ   202.57 (+0.56%)
CGC   15.33 (-3.22%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.28 (+0.82%)
ACB   2.85 (-13.37%)
F   8.95 (+1.82%)
PRI   131.16 (+0.74%)
BAC   32.88 (+0.55%)
DIS   144.93 (-1.51%)
S&P 500   3,113.99 (+0.56%)
DOW   27,928.81 (+0.53%)
QQQ   202.57 (+0.56%)
CGC   15.33 (-3.22%)
BABA   185.30 (+1.37%)
GE   11.50 (+1.86%)
T   39.28 (+0.82%)
ACB   2.85 (-13.37%)
F   8.95 (+1.82%)
PRI   131.16 (+0.74%)
BAC   32.88 (+0.55%)
DIS   144.93 (-1.51%)
Log in

Biomerica Stock Price, Forecast & Analysis (NASDAQ:BMRA)

$3.03
-0.01 (-0.33 %)
(As of 11/15/2019 01:06 PM ET)
Today's Range
$2.83
Now: $3.03
$3.03
50-Day Range
$2.94
MA: $3.12
$3.28
52-Week Range
$1.60
Now: $3.03
$3.69
Volume2,700 shs
Average Volume19,007 shs
Market Capitalization$29.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
CUSIPN/A
Phone949-645-2111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.20 million
Book Value$0.41 per share

Profitability

Net Income$-2,390,000.00

Miscellaneous

Employees54
Market Cap$29.75 million
Next Earnings Date1/21/2020 (Estimated)
OptionableNot Optionable

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.


Biomerica (NASDAQ:BMRA) Frequently Asked Questions

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) issued its quarterly earnings results on Wednesday, October, 16th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.01. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.52 million. Biomerica had a negative net margin of 47.77% and a negative return on equity of 61.29%. View Biomerica's Earnings History.

When is Biomerica's next earnings date?

Biomerica is scheduled to release their next quarterly earnings announcement on Tuesday, January 21st 2020. View Earnings Estimates for Biomerica.

What price target have analysts set for BMRA?

1 brokers have issued 12-month price objectives for Biomerica's shares. Their forecasts range from $6.30 to $6.30. On average, they anticipate Biomerica's share price to reach $6.30 in the next year. This suggests a possible upside of 107.9% from the stock's current price. View Analyst Price Targets for Biomerica.

What is the consensus analysts' recommendation for Biomerica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biomerica.

Has Biomerica been receiving favorable news coverage?

News headlines about BMRA stock have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biomerica earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Biomerica.

Are investors shorting Biomerica?

Biomerica saw a decline in short interest in October. As of October 31st, there was short interest totalling 12,500 shares, a decline of 7.4% from the September 30th total of 13,500 shares. Based on an average daily trading volume, of 22,900 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.2% of the shares of the stock are short sold. View Biomerica's Current Options Chain.

Who are some of Biomerica's key competitors?

What other stocks do shareholders of Biomerica own?

Who are Biomerica's key executives?

Biomerica's management team includes the folowing people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 53)
  • Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68)

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $3.03.

How big of a company is Biomerica?

Biomerica has a market capitalization of $29.75 million and generates $5.20 million in revenue each year. The company earns $-2,390,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Biomerica employs 54 workers across the globe.View Additional Information About Biomerica.

What is Biomerica's official website?

The official website for Biomerica is http://www.biomerica.com/.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.


MarketBeat Community Rating for Biomerica (NASDAQ BMRA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe BMRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel